CHARLES TOWN, W.Va., Oct. 23 /PRNewswire-FirstCall/ -- After five successful years of steady growth, ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) announced today that it is celebrating five years of continued operations by shipping out its 50,000th order, and sales growth that indicates reaching 100,000 orders by the end of 2008.
"Our ReBuilder for Diabetic Peripheral Neuropathy has been a steady winner for us. Today we celebrate our 50,000th shipment. Some of these orders were for the ReBuilder electronic device, some were for the consumable support products that the patients consume, and others were for the Phillips Molluscum Treatment System(TM) and its consumables. The ReBuilder System(R) itself can stand alone, and produces 100% profit margins, however, we have offered accessories and refills on its consumables and all together, with the new customers and the returning customers who re-order their supplies, we are happy to have reached this milestone," says David B. Phillips, Ph.D. CEO of ReBuilder Medical Technologies, Inc.
"Our sales have been growing regularly and as a result of about 33% of our sales coming from referrals from happy customers, and the new marketing partners, we hope to ship an additional 50,000 orders, in the next year, and have geared production, inventory control, and general management practices accordingly. It takes new practices to cope with the sales and customer service any company is accustomed to," said David B. Phillips, Company CEO, at the end of this interview. The anticipated 50,000 shipments should take us to the next level in mass marketing.
About ReBuilder Medical Technologies, Inc.:
ReBuilder Medical Technologies, Inc. is a manufacturer of medical devices and innovative technologies founded by world-renowned medical device inventor David B. Phillips, Ph.D. The company's flagship product is its FDA registered ReBuilder System(R), used for treating peripheral neuropathy. Unlike current therapies for neuropathy (nerve disease) that depend on prescription drugs with powerful side effects, the ReBuilder System(R) is a portable, battery-powered medical product that provides a unique, non-surgical treatment which is non-invasive, has no side effects and can actually strengthen muscles while increasing blood flow.
ReBuilder Medical Technologies, Inc. also manufactures the Phillips Molluscum Treatment System(TM) for treating the skin disease Molluscum Contagiosum which primarily affects children. This system uses its proprietary form of micronized amorphous silver ions to disable the molluscum pathogen without side effects. The company is currently performing research and development on a number of other products as well.
ReBuilder Medical Technologies, Inc. is located in Charles Town, WV. CEO, Dr. David Phillips, Ph.D. is best known for inventing the very first infrared ear thermometer. Dr. Phillips also was responsible for the GST System, which is used for the early detection of breast cancer, and the AcuPen, a hand-held device that provides the benefits of acupuncture without the use of needles.
More information on ReBuilder Medical Technologies, Inc. and its products can be found at: http://www.rebuildermedical.com.
Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.
|SOURCE ReBuilder Medical Technologies, Inc.|
Copyright©2007 PR Newswire.
All rights reserved